Safety test of HRS-7156 in healthy adults
Official title: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single and Multiple Ascending Oral Doses of HRS-7156 in Healthy Participants
Run by Shandong Suncadia Medicine Co., Ltd. · NCT07601087 · Data updated 2026-11-12
This study tests whether HRS-7156 is safe and tolerated in healthy adults aged 18–55.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 55 Years |
| Sex | All |
| Enrollment | 66 (estimated) |
| Sponsor | Shandong Suncadia Medicine Co., Ltd. Industry-sponsored |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | June 12, 2026 |
| Main results expected | September 2026 |
| Study ends | September 2026 |
| Registry record updated | August 24, 2026 |
| Trial ID | NCT07601087 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy men and women aged 18–55 with body weight ≥45 kg, BMI 18.5–30, and who can use effective contraception until after the last dose.
✕Probably not a fit
Individuals with significant health issues, recent major surgery or infection, or those unable to comply with contraception requirements are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 1 interventional trial assessing safety, tolerability, and how the body handles HRS-7156, including pharmacokinetics and pharmacodynamics, in healthy participants. Participants receive either the active drug or a placebo in a controlled setting. The study screens for overall health, enrolls eligible volunteers, and follows them to monitor any adverse effects and how the drug behaves in the body. The trial is conducted at a single center in Shanghai under lead sponsor Shandong Suncadia Medicine Co., with strict inclusion and exclusion criteria to minimize risk. Results will inform dose selection and safety profile for future research in patients with heart failure.
Why it matters
Potential benefit: Participants may not experience direct clinical benefits, but the study could help determine safe dosing for future patient trials.
How similar studies have gone: Phase 1 trials of similar agents have established safety and pharmacokinetic profiles in healthy volunteers; this study follows established early-phase methods.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Healthy men and women aged 18 to 55 years old at informed consent signing; 2. Male body weight ≥50 kg, female ≥45 kg; BMI 18.5 to 30 kg/m² at screening and baseline; 3. Have no clinically significant abnormalities at screening and baseline; 4. Fertile females and males with fertile female partners: effective contraception 2 weeks before consent, and sustained until 1 week after the last dose (abstinence or highly effective contraception); no sperm/egg donation. Exclusion Criteria: 1. A history or current severe diseases of multiple systems, or other diseases interfering with trial results; 2. Severe infection, trauma, major surgery within 3 months before screening; planned surgery during the trial; 3. Blood donation/severe blood loss (≥400 mL) within 8 weeks, blood transfusion within 4 weeks before screening; planned blood donation during the trial; 4. History of drug abuse/dependence; positive urine drug test at screening.Participation in other clinical trials within 3 months before screening or planned; 5. participation during the trial; within 5 half-lives of a prior drug (whichever is longer); 6. Smoking history (≥5 cigarettes/day) within 4 weeks before screening; inability to abstain from tobacco during the trial; positive smoke screening at screening/baseline; 7. Positive for HBsAg, HIV antibody, Treponema pallidum antibody or HCV antibody at screening; 8. Special dietary requirements and inability to comply with the unified diet; 9. Difficulty in swallowing/venous blood collection; intolerance to intensive blood sampling; 10. Other circumstances deemed unsuitable for trial participation by Researcher.
Where it's running
-
Zhongshan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Study coordinator: Kaiyun Zhang
- Email: kaiyun.zhang.kz38@hengrui.com
- Phone: +86-0518-82342973
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using Apple Watch data to predict heart failure outcomes
This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.
-
Comparing Aortix Device to Diuretics for Acute Heart Failure
This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.
-
Myocardial Energetics Across Cardiovascular Disease Spectrum Using 31P-MRS
Researchers are testing whether phosphorus-31 magnetic resonance spectroscopy (31P-MRS) can map heart energy metabolism across healthy people and patients with various heart conditions.
-
Tailored digital support to cut sedentary time in long-term cardiac rehab
In adults in a long-term cardiac rehabilitation program, this study tests whether a personalized behavioural program with digital tools can reduce daily sitting time.
-
NT-proBNP–guided heart failure screening for people 65+ in rural China
This study tests whether using NT-proBNP blood tests to guide heart failure screening in adults 65 and older in rural China can find unrecognized heart problems more effectively than symptom-based screening.
-
Voice-based detection of heart failure deterioration using Noah Labs Vox
This study tests whether a voice-analysis app can flag worsening heart failure in adults by comparing its alerts to standard weight-based monitoring.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.